公开(公告)号：US20190203192A1

公开(公告)日：2019-07-04

申请号：US15859500

申请日：2017-12-30

Applicant: Development Center for Biotechnology

Inventor： Jei-Hwa YU ,  Iok-U FONG ,  Su-Yi HSU ,  Chih-Yung HU ,  Chia-Cheng WU

IPC: C12N9/64 ,  C07K16/22 ,  C07K14/575 ,  C07K16/28 ,  A61P25/00 ,  A61P35/00 ,  A61P37/02 ,  A61P31/00

CPC classification number: C12N9/6445 ,  A61K39/395 ,  A61K2039/505 ,  A61P25/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  C07K14/5759 ,  C07K16/22 ,  C07K16/2803 ,  C07K16/46 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/30

Abstract: An antibody prodrug capable of being selectively activated in a central nervous system (CNS) by protease KLK6 includes an antibody for treating a disease or disorder in the CNS; a KLK6 cleavable peptide fused to an N-terminus of a heavy chain and/or a light chain of the antibody; and a blocker fused to an N-terminus of the KLK6 cleavable peptide. The disease or disorder is a cancer, inflammatory disease, autoimmune disease, infectious disease, or neuron degeneration disease.

公开(公告)号：US20180371088A1

公开(公告)日：2018-12-27

申请号：US16016414

申请日：2018-06-22

Applicant: Development Center for Biotechnology

Inventor： Chia-Cheng WU ,  Tzu-Yin LIN ,  Chao-Yang HUANG ,  Yu-Jung CHEN ,  Jei-Hwa YU ,  Chen-Li CHIEN

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00

Abstract: An asymmetric heterodimeric antibody includes a knob structure formed in a CH3 domain of a first heavy chain; a hole structure formed in a CH3 domain of a second heavy chain, wherein the hole structure is configured to accommodate the knob structure so that a heterodimeric antibody is formed; and a T-cell targeting domain fused to the CH3 domain of the first heavy chain or the second heavy chain, wherein the T-cell targeting domain binds specifically to an antigen on the T-cell. The T-cell targeting domain is a ScFv or Fab derived from an anti-CD3 antibody. The asymmetric heterodimeric antibody may have L234A and L235A mutations or L235A and G237A such that its effector binding is compromised.

公开(公告)号：US20180371089A1

公开(公告)日：2018-12-27

申请号：US16016525

申请日：2018-06-22

Applicant: Development Center for Biotechnology

Inventor： Chia-Cheng WU ,  Tzu-Yin LIN ,  Yu-Jung CHEN ,  Chao-Yang HUANG

IPC: C07K16/28

Abstract: A bispecific anti-Globo H antibody includes an anti-Globo H antibody that binds specifically to Globo H; and a T-cell targeting domain fused to a CH3 domain of a heavy chain of the anti-Globo H antibody, wherein the T-cell targeting domain binds specifically to an antigen on T-cells; and wherein the anti-Globo H antibody comprises mutations at an effector binding site such that the bispecific anti-Globo H antibody has a diminished effector function. The T-cell targeting domain is a ScFv or Fab from an anti-CD3 antibody.

公开(公告)号：US20190309092A1

公开(公告)日：2019-10-10

申请号：US16318615

申请日：2017-07-20

Applicant: DCB-USA LLC ,  Development Center for Biotechnology

Inventor： Chih-Yung HU ,  Chao-Yang HUANG ,  Yu-Jung CHEN ,  Chia-Cheng WU ,  Chien-Tsun KUAN ,  Chia-Hsiang LO ,  Hsien-Yu TSAI

IPC: C07K16/46 ,  C07K16/18 ,  C07K16/30 ,  C07K16/22 ,  C07K16/28 ,  C07K16/24 ,  C07K16/32

Abstract: The present invention provides a modified antigen-binding Fab fragment. An antigen-binding molecule comprising the antigen-binding Fab fragment and a composition comprising the molecule are also provided.